YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers

Molecular‐targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2‐positive breast cancer. However, acquired resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Tatsuaki, Yamamoto, Hiromasa, Suzawa, Ken, Tomida, Shuta, Miyauchi, Shunsaku, Araki, Kota, Nakata, Kentaro, Miura, Akihiro, Namba, Kei, Shien, Kazuhiko, Soh, Junichi, Shien, Tadahiko, Kitamura, Yoshihisa, Sendo, Toshiaki, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060468/
https://www.ncbi.nlm.nih.gov/pubmed/31856375
http://dx.doi.org/10.1111/cas.14289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060468/
https://www.ncbi.nlm.nih.gov/pubmed/31856375
http://dx.doi.org/10.1111/cas.14289

Ejemplares similares